Skip to content

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

Menu

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

August 2022

ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

Portfolio News / By Karina Tin

August 11, 2022

RAPT Therapeutics Reports Second Quarter 2022 Financial Results

Portfolio News / By Karina Tin

August 11, 2022

Surrozen Reports Second Quarter 2022 Financial Results

Portfolio News / By Karina Tin

August 11, 2022

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results & Provides Business Update

Portfolio News / By Karina Tin

August 10, 2022

eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Portfolio News / By Karina Tin

August 9, 2022

eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer

Portfolio News / By Karina Tin

August 8, 2022

Kallyope’s Newly Established Clinical Development Advisory Board Joined By Renowned Biopharma Leaders

Portfolio News / By Karina Tin

August 5, 2022

NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results

Portfolio News / By Karina Tin

August 4, 2022

Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Portfolio News / By Karina Tin

August 3, 2022

Search for:

Recent Posts

RAPT Therapeutics Reports First Quarter 2023 Financial Results
Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
Kallyope Receives $8.2 Million Grant to Identify Novel Interventions for Children and Undernourished Pregnant Women and Mothers Experiencing Environmental Enteric Dysfunction
eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Recent Comments

Archives

Categories

Portfolio News
TCG News

The Column Group

Copyright © 2022. The Column Group | Privacy Policy | Terms of Use
Website developed by CP Communications

Scroll to Top